Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698987 | Clinical Oncology | 2013 | 8 Pages |
Abstract
These interim data indicate no early evidence of detriment to quality of life, overall survival or QALYs for patients allocated to OSC alone. They provide key information for discussing the trial with patients and strengthen the argument for continuing QUARTZ to definitively answer this important clinical question.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R.E. Langley, R.J. Stephens, M. Nankivell, C. Pugh, B. Moore, N. Navani, P. Wilson, C. Faivre-Finn, R. Barton, M.K.B. Parmar, P.M. Mulvenna, on behalf of the QUARTZ Investigators on behalf of the QUARTZ Investigators,